Join our daily newsletter At The Bell to receive exclusive market insights
- Imugene (IMU) has completed the recruitment for its phase two gastric cancer trial which is testing its HER-Vaxx immunotherapy drug
- The trial will be conducted in Asia, Eastern Europe and India where there is said to be a high prevalence of gastric cancer
- HER-Vaxx aims to produce an antibody response against the HER-2 protein which causes cancer growth
- The trial will test the efficacy, safety and immune response in patients whose cancer is overexpressing the HER-2 protein
- IMU is up 5 per cent and shares are trading at 10.5 cents
Imugene (IMU) has completed the recruitment for its phase two gastric cancer trial which is testing its HER-Vaxx immunotherapy drug.
HER-Vaxx is designed to produce an antibody response against a cancer growth signal receptor protein called ‘HER-2’, which is found on the cell surface in gastric and breast cancers.
Recently, the Independent Data Monitoring Committee (IDMC) conducted a review of the HER-Vaxx phase two trial. Pleasingly, there were no safety concerns and the preliminary data was deemed favourable.
However, the IDMC recommended the company reduce the overall number of patients in the study considering the strong signal observed in the data. Following its guidance, Imugene reduced the number of patients to 36 patients.
“I am excited to report that we have completed recruitment in the HER-Vaxx phase two clinical trial,” Managing Director and CEO Leslie Chong said.
“This is an important achievement for Imugene and the many medical professionals seeking treatments for patients with advanced gastric cancer who often have very few medical options,” Leslie added.
The study will be conducted in Asia, Eastern Europe and India, where there is reportedly a high prevalence of gastric cancer.
The trial will test the efficacy, safety and immune response in patients with metastatic gastric cancer overexpressing the HER-2 protein.
IMU is up 5 per cent and shares are trading at 10.5 cents at 11:23 am AEDT.
